PremiumThe FlyAssembly Biosciences initiated with a Buy at Guggenheim Guggenheim starts Assembly Biosciences with a Buy ahead of clinical readouts Assembly Biosciences files $250M mixed securities shelf PremiumThe FlyAssembly Biosciences announces interim PK, efficacy from Phase 1b study Assembly Biosciences announces $30.1M investment, funding from Gilead Assembly Biosciences Reports Q3 2024 Financials and Strategic Advances PremiumThe FlyAssembly Biosciences upgraded to Buy from Hold at Jefferies Eleven option delistings on August 19th Assembly Biosciences reports Q2 EPS ($1.98) , one estimate ($2.23) 
